NCT06237101 Remifentanil Effect on Burst Suppression Ratio
| NCT ID | NCT06237101 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Chile |
| Condition | Anesthesia, Intravenous |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2024-03-01 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to determine whether remifentanil has a facilitating effect on the generation of burst suppression by propofol in adult patients (18-60 years) candidates for elective surgery who require remifentanil and American Society of Anesthesiology (ASA) classification I or II. The main question it aims to answer are: • To determine whether remifentanil has a facilitating effect on the generation of burst suppression by propofol. Participants will undergo general anesthesia with remifentanil and propofol sequentially. After loss of consciousness, remifentanil will be adjusted to a medium or high concentration randomly and it will be determined at what concentration of propofol the burst suppressions are generated. Then, the concentrations of propofol that generate burst suppression associated with either a medium or high concentration of remifentanil will be compared.
Eligibility Criteria
Inclusion Criteria: * American Society of Anesthesiology I or II * Elective surgery of low or intermediate risk Exclusion Criteria: * Neurological disease * Psychiatric disease * Use of psychoactive drugs or opioids * Altered basal state of consciousness * Allergy to propofol * Body mass index \> 35 kg/m2 * Pre-existing renal, cardiac and/or hepatic dysfunction * Patient's refusal to participate
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06237101 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Anesthesia, Intravenous. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06237101 currently recruiting?
Yes, NCT06237101 is actively recruiting participants. Contact the research team at apenna@uchile.cl for enrollment information.
Where is the NCT06237101 trial being conducted?
This trial is being conducted at Santiago, Chile, Santiago, Chile.
Who is sponsoring the NCT06237101 clinical trial?
NCT06237101 is sponsored by University of Chile. The trial plans to enroll 20 participants.